TranS1 Inc. (Nasdaq:TSON) announced today that it will participate in the Canaccord Genuity Musculoskeletal conference in March.

Ken Reali, President and Chief Executive Officer, and Joe Slattery, Executive Vice President and Chief Financial Officer, are scheduled to present at the Canaccord Genuity Musculoskeletal Conference in Chicago, IL on Tuesday, March 19, 2013 at 11:20 am CT.

Institutional investors that wish to request a meeting with TranS1 should contact Canaccord Genuity.

About TranS1 Inc.

TranS1 is a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lumbar region. TranS1 currently markets the AxiaLIF® family of products for single and two level lumbar fusion, the VEOTM direct lateral access and interbody fusion system and the VectreTM posterior fixation system for lumbar fixation supplemental to AxiaLIF fusion. TranS1 was founded in May 2000 and is headquartered in Raleigh, North Carolina. For more information, visit www.trans1.com.

CONTACT: Investors:
         TranS1 Inc.
         Joseph P. Slattery, 910-332-1700
         Executive Vice-President and Chief Financial Officer
         
         Westwicke Partners
         Mark Klausner, 443-213-0501
         trans1@westwicke.com
Baxano Surgical, Inc. (MM) (NASDAQ:TSON)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Baxano Surgical, Inc. (MM) Charts.
Baxano Surgical, Inc. (MM) (NASDAQ:TSON)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Baxano Surgical, Inc. (MM) Charts.